WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”) (OTC: ACTC) announced today that it has received the initial $250,000 in funding from Transition Holdings Ltd, an Irish institutional investor. The Company previously announced that it would sell $500,000 of one-year 7% convertible debentures over the next 90 days. The proceeds will be used for working capital and general corporate purposes and will support operations while the Company seeks strategic partners for its advanced clinical programs.
